THE HAGUE, Netherlands, June 12, 2020 /PRNewswire/ -- Treatment of childhood cancer is a success story, particularly for acute lymphoblastic leukemia (ALL). More than 90% of ALL patients below 18 years of age are rescued with contemporary chemotherapy. However, the remaining 10% have resistant or reoccurring leukemia and require alternative treatment regimens. One of the most powerful leukemia therapies is hematopoietic stem cell transplantation from a donor (allogeneic HSCT). Approximately 50-80% of pediatric ALL patients that receive allogeneic HSCT are cured, 20% experience leukemic reoccurrence (relapse), and 10% die from complications.

Allogeneic HSCT is a multistep procedure:

For high-risk leukemia, the gold standard conditioning procedure is a combination of total body irradiation (TBI) and high dose chemotherapy. This approach is very effective in controlling leukemia in the conditioning step, but patients may experience highly negative consequences of this procedure later in life: sterility, growth retardation, lung problems, and secondary cancer.

Therefore, a large consortium of pediatric transplant experts initiated a global study to investigate whether chemotherapy-based conditioning could substitute TBI. The study is called FORUM (For Omitting Radiation Under Majority Age) and had to be stopped because chemotherapy-based conditioning had significantly poorer outcomes (i.e., lower overall survival rates) than the combination of TBI and chemotherapy. The researchers will now perform prospective monitoring to better define the advantages and limitations of various conditioning approaches.

Presenter:Dr Christina PetersAffiliation:Stem Cell Transplantation Unit, St. Anna Children's Hospital, Vienna, AustriaAbstract:#S102 TBI OR CHEMOTHERAPY BASED CONDITIONING FOR CHILDREN AND ADOLESCENTS WITH ALL: A PROSPECTIVE RANDOMIZED MULTICENTER-STUDY "FORUM" ON BEHALF OF THE AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP

Embargo: Please note that our embargo policy applies to all selected abstracts in the Press Briefings. For more information click here.

Logo - http://mma.prnewswire.com/media/622259/EHA_Logo.jpg

See the original post here:
EHA25Virtual: Combined Irradiation and Chemotherapy Better Prepares Children for Stem Cell Transplantation than Chemotherapy Alone - P&T Community

THE HAGUE, Netherlands, June 12, 2020 /PRNewswire/ -- Treatment of childhood cancer is a success story, particularly for acute lymphoblastic leukemia (ALL). More than 90% of ALL patients below 18 years of age are rescued with contemporary chemotherapy. However, the remaining 10% have resistant or reoccurring leukemia and require alternative treatment regimens. One of the most powerful leukemia therapies is hematopoietic stem cell transplantation from a donor (allogeneic HSCT). Approximately 50-80% of pediatric ALL patients that receive allogeneic HSCT are cured, 20% experience leukemic reoccurrence (relapse), and 10% die from complications.

Allogeneic HSCT is a multistep procedure:

For high-risk leukemia, the gold standard conditioning procedure is a combination of total body irradiation (TBI) and high dose chemotherapy. This approach is very effective in controlling leukemia in the conditioning step, but patients may experience highly negative consequences of this procedure later in life: sterility, growth retardation, lung problems, and secondary cancer.

Therefore, a large consortium of pediatric transplant experts initiated a global study to investigate whether chemotherapy-based conditioning could substitute TBI. The study is called FORUM (For Omitting Radiation Under Majority Age) and had to be stopped because chemotherapy-based conditioning had significantly poorer outcomes (i.e., lower overall survival rates) than the combination of TBI and chemotherapy. The researchers will now perform prospective monitoring to better define the advantages and limitations of various conditioning approaches.

Presenter:Dr Christina PetersAffiliation:Stem Cell Transplantation Unit, St. Anna Children's Hospital, Vienna, AustriaAbstract:#S102 TBI OR CHEMOTHERAPY BASED CONDITIONING FOR CHILDREN AND ADOLESCENTS WITH ALL: A PROSPECTIVE RANDOMIZED MULTICENTER-STUDY "FORUM" ON BEHALF OF THE AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP

Embargo: Please note that our embargo policy applies to all selected abstracts in the Press Briefings. For more information click here.

Logo - http://mma.prnewswire.com/media/622259/EHA_Logo.jpg

SOURCE European Hematology Association (EHA)

Go here to see the original:
EHA25Virtual: Combined Irradiation and Chemotherapy Better Prepares Children for Stem Cell Transplantation than Chemotherapy Alone - PR Newswire UK

ANI | New Delhi [India] July 4, 2017 Last Updated at 20:22 IST

Regenexx, the world's most advanced stem cell procedures for treating orthopedic conditions and sports injuries has entered in Mumbai. This is their second branch in Asia. It would offer two stem cell procedures using imaging and interventional orthopedic techniques to non-surgically repair and regenerate.

The first one is a same-day procedure where stem cells are harvested, isolated and re-implanted on the same day. The second one is blood-derived plasma-rich platelet procedure. They would help athletes and non-athletes overcome early, mild, moderate ortho problems in a way that is devoid of surgery.

Regenexx is the most advanced stem cell and platelet procedures for treating orthopedic injuries, arthritis and other degenerative conditions. These procedures offer non-surgical alternatives to commonly occurring musculoskeletal conditions. Patented Regenexx procedures use precise injections of your own stem cells or blood platelets to help your body's ability to heal damaged muscles, tendons, ligaments, cartilage, spinal disc and bone.

Regenexx Stem Cell Therapy and Platelet Procedures, avoid the need for invasive surgery, in turn eliminating any complications that are typically seen with surgeries.

"The only option till now was total knee replacement. Now with this technology we can heal and regenerate the lost tissues like cartilage, meniscus and ligaments to reverse the arthritis and in turn avoid any major surgery. Patients return to their loved activities in no time. We could also treat conditions like lower back pain, hip arthritis, bulging discs, ankle and shoulder rotator cuff tears with stem cells orthopedics procedure. Majority of these are lifestyle related conditions," said Dr. Venkatesh Movva, MD, Regenexx India.

Regenexx procedures are image-guided needle-based procedures, so the downtime for recovery is minimal or none. These are truly ambulatory procedures without the need for hospitalisation. The procedure process involves harvesting bone marrow stem cells, using our sophisticated lab process to separate cells and precise image guided injections into the target joints in an outpatient setting.

"Regenexx procedures are out-patient procedues and that patients can walk out of the treatment the same day. Physiotherapy team at Regenexx will help patients make the necessary changes to their physical movements so that the procedures are effective," said Dr. Apurv Mahalle, MGIMS.

There is no alternative for arthritis patients but to wait until the joint is bad enough for a replacement and then go through a surgery. Regenexx procedures are going to help these patients get back to the normal routine without the necessity of a replacement surgery.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Regenexx, the world's most advanced stem cell procedures for treating orthopedic conditions and sports injuries has entered in Mumbai. This is their second branch in Asia. It would offer two stem cell procedures using imaging and interventional orthopedic techniques to non-surgically repair and regenerate.

The first one is a same-day procedure where stem cells are harvested, isolated and re-implanted on the same day. The second one is blood-derived plasma-rich platelet procedure. They would help athletes and non-athletes overcome early, mild, moderate ortho problems in a way that is devoid of surgery.

Regenexx is the most advanced stem cell and platelet procedures for treating orthopedic injuries, arthritis and other degenerative conditions. These procedures offer non-surgical alternatives to commonly occurring musculoskeletal conditions. Patented Regenexx procedures use precise injections of your own stem cells or blood platelets to help your body's ability to heal damaged muscles, tendons, ligaments, cartilage, spinal disc and bone.

Regenexx Stem Cell Therapy and Platelet Procedures, avoid the need for invasive surgery, in turn eliminating any complications that are typically seen with surgeries.

"The only option till now was total knee replacement. Now with this technology we can heal and regenerate the lost tissues like cartilage, meniscus and ligaments to reverse the arthritis and in turn avoid any major surgery. Patients return to their loved activities in no time. We could also treat conditions like lower back pain, hip arthritis, bulging discs, ankle and shoulder rotator cuff tears with stem cells orthopedics procedure. Majority of these are lifestyle related conditions," said Dr. Venkatesh Movva, MD, Regenexx India.

Regenexx procedures are image-guided needle-based procedures, so the downtime for recovery is minimal or none. These are truly ambulatory procedures without the need for hospitalisation. The procedure process involves harvesting bone marrow stem cells, using our sophisticated lab process to separate cells and precise image guided injections into the target joints in an outpatient setting.

"Regenexx procedures are out-patient procedues and that patients can walk out of the treatment the same day. Physiotherapy team at Regenexx will help patients make the necessary changes to their physical movements so that the procedures are effective," said Dr. Apurv Mahalle, MGIMS.

There is no alternative for arthritis patients but to wait until the joint is bad enough for a replacement and then go through a surgery. Regenexx procedures are going to help these patients get back to the normal routine without the necessity of a replacement surgery.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

ANI

http://bsmedia.business-standard.com/_media/bs/wap/images/bs_logo_amp.png 177 22

Read this article:
Regen Ortho sport facility launched - Business Standard

Hot air: Triona McCarthy on how to smeel good

Independent.ie

Want to smell good, look good, and feel fantastic? The scentsational Triona McCarthy shows us her weekly round-up of lotions and potions to keep you looking hawt!

http://www.independent.ie/life/hot-air-triona-mccarthy-on-how-to-smeel-good-35845624.html

http://www.independent.ie/incoming/article35592585.ece/c3491/AUTOCROP/h342/mg%20Trionna.jpg

Want to smell good, look good, and feel fantastic? The scentsational Triona McCarthy shows us her weekly round-up of lotions and potions to keep you looking hawt!

Created by an Irish female natural beauty entrepreneur, YourBeautyTonic has everything your skin needs to boost beauty. Its key ingredients, collagen and hyaluronic acid, are the building blocks of youthful skin, and it also contains vitamins and minerals.

YourBeautyTonic, above, costs 59.95 for 30 days' supply, and is available from independent health stores, selected pharmacies and online at yourtonic.com

WAX ON, WAX OFF...

I'm off to Inchydoney, in west Cork this weekend, so I'm waxed.

The gals at Brazilia are so profesh, and they make the waxing experience so easy, painless, and, actually, almost pleasurable.

I don't know if I'm quite ready to rock a teeny-weny little bikini like Emily Ratajkowski, above, but you never know!

Brazilia, 50 South William St, D2, tel: (01) 675-0000; 4 Sandyford Office Park, D18, tel: (01) 293-4858, or see brazilia.ie

LET US SPRAY

Image PREVENTION + Pure Mineral Sunscreen Spray 30+ SPF, below, 47.50, is so quick and effective. Before walking Maxi and Mini to Montessori in the morning, I cleanse and moisturise my face, and spray on this ultra-lightweight, anti-pollution, anti-aging, pure mineral sunscreen spray with superior UVA/UVB and infrared protection.

Infused with antioxidants and plant stem cells, it nourishes and hydrates my skin with organic ingredients, including jojoba and sweet almond oil - and, best of all, it's free of parabens and chemicals.

TRIONA'S TRICK

We have my kiddies, Maxi and Mini, to thank for this week's beauty trick. If, like me, you don't like your Beauty Blender sponge getting all grubby in the bottom of your make-up bag, simply pop it into an empty Kinder Egg container to protect it!

CULT PRODUCT

Inspired by Poppy Delevingne's wedding make-up, this Charlotte Tilbury Instant Look In A Palette, above, 69, in Beauty Glow, is perfect for popping in your purse for on the go - goof-proof glam, as it has everything a gal needs to get gorgeous.

This is the fourth versh released, and definitely my fave, as the rose-gold and bronze tones are darker and more dramatic. I found the previous versions a bit too wishy-washy colour-wise, whereas this slays.

TRIONA'S TOP TIP

'Summer lovin' had me a blast,

Summer lovin' happened so fast'

I love a bit of Grease, but not on my head!

However, if like me, you have long hair and it's leaving you hot and bothered this summer, why not try a chic model-off-duty topknot.

Kate Moss pulls this look off so well, making it look stylish and hot, yet so nice and cool, as the hair's up and off your neck.

Best of all, a high bun has a cheekbone-lifting effect, so it's a win-win.

Slick your hair back with Shockwaves Ultra Strong Power Hold Gel, above, 2.50, which also helps fight frizzy fine hairs around your forehead, making you look hot in a good way!

If you're hitting the beach, make sure to layer this Philip Kingsley Sun Shield, below, 30, marksandspencer.ie, as hair can burn just like the skin when it's left unprotected.

This super-lightweight nourishing mist provides an invisible shield of protection over the hair. I always make sure I have it in my beach bag for myself and Will and the kids.

Best of all, it guards against colour fade from sun exposure, and diminishes damage and dryness caused by UV rays, chlorine and salt water.

'Summer days driftin' away, to uh-oh those summer nights'

Sunday Independent

Visit link:
Hot air: Triona McCarthy on how to smeel good - Independent.ie

In an autologous BMT procedure, the healthy stem cells from the patient are taken out and preserved

IANS | New Delhi April 21, 2017 Last Updated at 05:00 IST

A team of doctors in New Delhi has successfully treated a 24-year-old girl suffering from Multiple Sclerosis (MS) with bone marrow transplant (BMT).

Kanika Juneja was diagnosed with MS an autoimmune disorder where the body's immune system starts attacking the protective sheet covering the nerve cells in the brain and the spinal cord.

She went through several rounds of treatments but could not be cured. Juneja got another chance at life at Fortis Healthcare where the doctors treated her with BMT.

"In an autologous BMT procedure, the healthy stem cells from the patient are taken out and preserved. Chemotherapy is then administered to reset the body's immunity and then the stem cells are injected back to rescue the person from the side effects of chemotherapy. After the surgery, the patient is kept under isolation for a few months to ensure he/she does not contract any infection," explained Dr Rahul Bhargava, Director, Clinical Hematology and Bone Marrow Transplant, Fortis Memorial Research Institute (FMRI).

Since conventional steroid injections and immune therapy are expensive and don't promise a cure, Bhargava thought of going for a BMT for Juneja.

Juneja is now actively involved in raising awareness about MS amongst the community through social media.

"I had just completed my college education when I was diagnosed with multiple sclerosis. I was lucky because I got diagnosed within a week of my symptoms and could avail treatment options faster," Juneja said.

"In this case, we have proved that bone marrow transplant can be seen as a successful alternate treatment option for multiple sclerosis patients, giving them a fresh shot at life," added Dr Simmardeep Singh Gill, Zonal Director, FMRI, in a statement.

Currently, there are 2.3 million people living with multiple sclerosis worldwide.

A team of doctors in New Delhi has successfully treated a 24-year-old girl suffering from Multiple Sclerosis (MS) with bone marrow transplant (BMT).

Kanika Juneja was diagnosed with MS an autoimmune disorder where the body's immune system starts attacking the protective sheet covering the nerve cells in the brain and the spinal cord.

She went through several rounds of treatments but could not be cured. Juneja got another chance at life at Fortis Healthcare where the doctors treated her with BMT.

"In an autologous BMT procedure, the healthy stem cells from the patient are taken out and preserved. Chemotherapy is then administered to reset the body's immunity and then the stem cells are injected back to rescue the person from the side effects of chemotherapy. After the surgery, the patient is kept under isolation for a few months to ensure he/she does not contract any infection," explained Dr Rahul Bhargava, Director, Clinical Hematology and Bone Marrow Transplant, Fortis Memorial Research Institute (FMRI).

Since conventional steroid injections and immune therapy are expensive and don't promise a cure, Bhargava thought of going for a BMT for Juneja.

Juneja is now actively involved in raising awareness about MS amongst the community through social media.

"I had just completed my college education when I was diagnosed with multiple sclerosis. I was lucky because I got diagnosed within a week of my symptoms and could avail treatment options faster," Juneja said.

"In this case, we have proved that bone marrow transplant can be seen as a successful alternate treatment option for multiple sclerosis patients, giving them a fresh shot at life," added Dr Simmardeep Singh Gill, Zonal Director, FMRI, in a statement.

Currently, there are 2.3 million people living with multiple sclerosis worldwide.

IANS

http://bsmedia.business-standard.com/_media/bs/wap/images/bs_logo_amp.png 177 22

More here:
Multiple Sclerosis patient successfully treated with bone marrow transplant - Business Standard

VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 13, 2017) -

NOT FOR DISSEMINATION IN THE UNITED STATES

Editors Note: There is a photo associated with this press release.

Woodrose Ventures Corporation (TSX VENTURE:WRS.H) ("Woodrose" or the "Company") is pleased to announce that it has entered into an agreement (the "Agreement") dated March 10, 2017 to acquire all of the shares of Novoheart Holdings Ltd. ("Novoheart"), a global stem cell biotechnology company dedicated to human heart engineering (the "Transaction"). Novoheart develops products and provides services focused on engineering prototypes of bio-artificial human heart tissues and chambers for drug discovery, cardiotoxicity screening, disease modelling and therapeutic applications.

The Transaction will constitute a "reverse-takeover" of Woodrose in accordance with the policies of the TSX Venture Exchange (the "TSXV") and the reactivation of Woodrose, which is currently a NEX-listed issuer.

About Novoheart

Novoheart is a global stem cell biotechnology company headquartered in Hong Kong with R&D Innovation Centres being set up in the United States. Novoheart's mission is to revolutionize drug discovery and the development of heart therapeutics with its range of proprietary bioengineered human heart constructs, collectively known as the MyHeart platform, and to further develop them into transplantable heart grafts for cell-based regenerative therapies with superior safety and efficacy. Its scientific team has pioneered a range of best-in-class bioengineering technologies and constructed the world's first human mini-heart "novoHeart" with which the Novoheart team intends to revolutionize:

1) Pre-clinical drug discovery, cardiotoxicity screening and heart disease modelling;

2) Post-discovery, clinical development of novel therapeutics; and

3) Pre-clinical and clinical development of cell-based cardiac regenerative therapies.

Novoheart's immediate focus is to innovate and accelerate the lengthy, expensive and inefficient drug development process. The development of a new drug candidate typically costs US$2-4bn and takes 10+ years (Tufts Centre for the Study of Drug Development, Tufts CSDD R&D Cost Study 2014) with extremely poor success rates of <1% of initial drug candidates making it to market (Willmann et al. 2008, Nature Reviews Drug Discovery 7, 591-607). The primary cause for drug withdrawal and attrition is heart toxicity. Despite substantial pre-human R&D costs (~30% of the entire process), conventional non-human and non-cardiac cell and animal models are poorly predictive of human responses, leading to false negative and false positive pre-clinical results that compromise the overall successes (Chen et al. 2016, Nature Reviews Cardiology 13, 333-349).

Novoheart's intellectual property portfolio, including the human "heart-in-a-jar" (novoHeart) and other related next-generation technologies of the MyHeart platform (see figure below) are unique solutions that help bridge the gap between pre-clinical and clinical drug trials. The MyHeart platform provides advanced human heart surrogates for pre-screening of drug formulas and the elimination of toxic compounds early on in the drug development process, minimizing the risk towards patients. Significantly, the MyHeart Platform provides real time data on the effects of drug formulations enabling drug development companies to undertake "on-the-fly" reformulation of drug candidates to optimize efficacy and toxicological profiles. With Novoheart's technologies, we aim to significantly reduce pre-clinical R&D time and costs, and importantly, improve trial successes. It is anticipated that drug screening results using Novoheart's human engineered tissues would be accepted as reliable indicators for toxicity and efficacy, thereby qualifying the test compounds for accelerated drug development.

Novoheart adopts a hybrid business model by:

These products and services are designed to significantly reduce the time, cost, and use of animal models, as well as improve patient safety, and facilitate pharmaceutical discovery and development. Novoheart is currently working with leading academic and pharmaceutical partners to innovate drug discovery and toxicity screening protocols. Our targeted clients are pharmaceutical companies, government units, and research institutions.

Novoheart was incorporated in 2014 pursuant to the laws of British Virgin Islands (BVI) and its controlling shareholder is Medera Group Limited, a BVI entity. Novoheart has one wholly owned Hong Kong subsidiary "Novoheart Limited" ("Novoheart Hong Kong") which is the group operating entity.

Novoheart Hong Kong was incorporated in January 2014 by founder and CEO Prof. Ronald Li, with scientific co-founders Prof. Kevin Costa and Prof. Michelle Khine.

Novoheart's foundational technologies are the direct outcome of over 15 years of research effort supported by R&D investments amounting to approximately USD30MM. These research efforts, performed at Johns Hopkins University, Icahn School of Medicine at Mount Sinai, University of California Irvine, University of California Davis, and the University of Hong Kong by our scientific founders, have received major recognitions such as American Heart Association's Best Study of 2005, Ground-breaking Study of 2006, and Late-breaking Studies of 2002, 2003, 2005 and 2007, and the Spirit of Hong Kong Innovating for Good Award in 2015. The "human-heart-in-a-jar" technology was selected by Google's Solve For X as a Moonshot Project in 2015.

Novoheart's scientific founders and advisors are renowned pioneering leaders in the stem cell and cardiac space, with a successful track record in developing and commercializing ground-breaking technologies. In September 2014, Novoheart established its R&D base and office in the Hong Kong Science Park, where it continues to innovate solutions for drug discovery and human heart tissue engineering.

In December 2014, Novoheart signed a strategic partnership with a major global pharmaceutical company (the "Global Pharma Partner") headquartered in New York City to validate the MyHeart platform. The success of this validation process has resulted in follow on income-generating projects.

In January 2015, Novoheart's R&D proposal to develop bio-artificial heart tissues for drug screening received 50/50 matched funding from the Innovation & Technology Commission (ITC) of the Government of Hong Kong, with a total project cost of over HK$21MM over 2 years. It was also the largest biotech project granted by ITC for that year. Novoheart owns all of the intellectual property generated from this project, and as a result of the R&D, Novoheart has applied or is in the application process for 3 new patents covering newly developed technology, including the human ventricular cardiac anisotropic sheet (hvCAS) as a powerful tool for detecting drug-induced arrhythmias with the results published in the prestigious international peer-reviewed bioengineering journal Advanced Materials (Shum et al. 2017, Advanced Materials, 29). Additionally, Novoheart holds exclusive worldwide licenses or options to acquire the same for technologies that constitute its MyHeart platform and future developments.

In December 2015, Novoheart signed a second contract with the Global Pharma Partner to build disease-specific engineered human heart tissues and chambers for drug discovery. The total project cost is US$726,000 over 1.5 years.

In February 2017, the Corporate Venture Fund (CVF) of the Hong Kong Science and Technology Parks Corporation (HKSTPC) completed an equity investment of approximately US$250,000 into Novoheart and an additional investment would be made at the Transaction.

Novoheart Financial Information

The following table includes a summary of certain financial information of Novoheart and is derived from its financial statements for the years ended June 30, 2016 and June 30, 2015.

Summary of the Transaction

Under the terms of the Agreement, the shareholders of Novoheart will receive an aggregate of 66,086,600 common shares of Woodrose on a post-Consolidation basis (see below) ("Woodrose Post-Consolidation Shares"). In addition, a finder's fee of 2,313,038 Woodrose Post-Consolidation Shares will be paid to Cynosure Private Equity Limited in connection with the Transaction.

In connection with the Transaction, Woodrose intends to complete a consolidation of all its outstanding common shares on the basis of 3.56878449 old common shares for each one new common share (the "Consolidation"). In addition, Woodrose intends to complete a non-brokered private placement (the "Private Placement") of 11,700,000 subscription receipts ("Subscription Receipts") at a price of CDN$0.50 per Subscription Receipt to raise gross proceeds of CDN$5,850,000, which will be held in escrow in accordance with the terms of a subscription receipt agreement (the "Subscription Receipt Agreement"). It is anticipated that the Subscription Receipt Agreement will provide that, upon completion of the Transaction, each Subscription Receipt will automatically convert into one Woodrose Post-Consolidation Share. The Subscription Receipt Agreement will also provide that, in the event the Transaction is terminated or does not complete within an agreed timeframe, the Subscription Receipts will be cancelled and the funds will be returned to the holders. Woodrose may pay cash fees in an amount not to exceed 7% of the gross proceeds (to a maximum of $364,000) to certain finders involved in the Private Placement and may issue finder's warrants ("Finder's Warrants"), in an amount not to exceed 7% of the number of Subscription Receipts issued (to a maximum of 728,000 Finders Warrants) each of which would entitle the holder to acquire one Woodrose Post-Consolidation Share at a price of CDN$0.50 for a period of two years following closing of the Private Placement. All securities issued pursuant to the Private Placement will be subject to a statutory hold period of four months and one day.

The Company intends to use the net proceeds of the offering to finance investment in drug discovery and screening, establish commercial partnerships, expand the current laboratory, hire additional research and development team members and for working capital and general corporate purposes.

Upon completion of the Transaction, it is anticipated that the Company will be classified as a Tier 2 Technology Issuer on the TSXV and will change its name to "Novoheart Holdings (BC) Limited" or such other name as is acceptable to the Board of Directors. Closing of the Transaction ("Closing") is subject to conditions precedent, that include, but are not limited to, the following:

The Transaction is an "arm's length" transaction (as defined by the policies of the TSXV). Woodrose intends to rely an exemption from the sponsorship requirements of the policies of the TSXV.

Proposed Management Team

Upon closing of the Transaction, the following directors and senior officers are anticipated to be appointed in replacement of Woodrose's current board and management:

Prof. Ronald Li, B.Sc. (Hons), Ph.D. (Proposed President, Chief Executive Officer and Director)

Prof. Ronald Li is a co-founder of Novoheart, and has been serving as the CEO since 2016. He is concurrently Director of Ming-Wai Lau Centre for Reparative Medicine, HK node, Karolinska Institutet (KI), Sweden, with a professorial cross appointment at the Dr. Li Dak-Sum Research Centre, The University of Hong Kong (HKU)-KI Collaboration in Regenerative Medicine of HKU. Prof. Li has been an advocate of stem cell technology for many years, starting from his career as Assistant Professor of Cardiology, and Cellular and Molecular Medicine at the Johns Hopkins University (JHU) School of Medicine. He founded and led the Human Embryonic Stem Cell Consortium when he was recruited in 2005 to become a tenured Associate Professor at the University of California, Davis, in light of state's USD3-billion stem cell initiative Proposition 71. Prof. Li was the Founding Director of the Stem Cell & Regenerative Medicine Consortium (SCRMC) at the University of Hong Kong (HKU) from 2010 to 2015. He also co-directed the Section of Cardiovascular Cell & Tissue Engineering in Icahn School of Medicine at Mount Sinai with Prof. Kevin Costa. Prof. Li has received multiple accolades and recognitions during his career, including the Spirit of Hong Kong Innovating for Good Award by the South China Morning Post (2015), the Top Young Faculty Award (2002, 2004), the Top Prize for the Young Investigator Basic Research (2001) and Top Postdoctoral Fellow Helen Taussig Award (2001) of JHU School of Medicine, Young Investigator Award 1st Prize from the Heart Rhythm Society (2002), and the Career Development Award from the Cardiac Arrhythmias Research & Education Foundation (2001).

Prof. Li graduated with his B.S. with honors in Biotechnology from University of Waterloo, Ontario, on Dean's List and his Ph.D. in Cardiology/Physiology at the University of Toronto.

Dr. Camie Chan, B.Sc. (Hons), M.Sc., Ph.D. (Proposed Chief Operating Officer and Director)

Dr. Camie Chan joined Novoheart Hong Kong as the Chief Operating Officer in 2016, after having served at HKU as the Deputy Director of the Faculty of Medicine Core Facility, a founding member of the Management Committee of the Stem Cell & Regenerative Medicine Consortium (SCRMC), and Assistant Professor in the Department of Anatomy, between 2010 and 2016. She has had extensive experience managing laboratory operations in her capacity at HKU, and her prior career as Assistant Professor at the University of California, Davis, and Assistant Investigator at the Shriners Hospital for Children. Dr. Chan is also a co-inventor of technology allowing mass production of human ventricular heart cells from pluripotent stem cells.

Dr. Chan graduated with her B.Sc. with honors at the University of Waterloo, followed by obtaining her M.Sc. degree in Medical Sciences and Ph.D. degree in Immunology at the University of Toronto, Canada. She then received postdoctoral training at the Sydney Kimmel Cancer Research Center at the Johns Hopkins University. She has garnered numerous awards in her career, including the prestigious National Institute of Allergy and Infectious Diseases (NIAID) Developmental Research Grant Award.

Prof. Kevin Costa, B.S., Ph.D. (Proposed Chief Scientific Officer)

Prof. Costa is Director of the Section of Cardiovascular Cell and Tissue Engineering at the Icahn School of Medicine at Mount Sinai in New York City. Prof. Costa was previously trained at the Johns Hopkins University and on the faculty as Associate Professor of Biomedical Engineering at Columbia University. As a "blue-blood" biomedical engineering (BME) expert (B.S. and M.S. in BME from Boston University, Ph.D. in BME from UC San Diego, and postdoc in BME from JHU and University of Washington) in cell and tissue biomechanics and cardiac tissue engineering, he has developed one of the first engineered cardiac tissue systems. Since 2009, he has been working with Prof. Ronald Li to translate such systems into human cells. Prof. Costa has received research funding from the Whitaker Foundation, the National Science Foundation (NSF) and the National Institutes of Health (NIH; NHLBI, NIBIB, and NIGMS). He was also a recipient of the prestigious Faculty Early Career Development (CAREER) Award from the NSF. Prof. Costa is an inventor of several cardiac tissue engineering technologies and one of the scientific co-founders of Novoheart Hong Kong.

Ms. Iris Lo, B. Comm. (Hons), CPA, CA (Proposed Chief Financial Officer)

Ms. Lo is a seasoned professional with expertise in corporate finance, mergers and acquisitions, accounting, and finance. Prior to joining Novoheart, Ms. Lo was the Director of Corporate Development & Analysis at Cardiome Pharma Corp., a Canadian public company dually listed on the TSX and NASDAQ (TSX: COM, NASDAQ: CRME). At Cardiome, she held responsibilities in equity and debt financing, corporate mergers and acquisitions, product licensing and distributions, financial planning and analysis, as well as regulatory and risk management. During her tenure at Cardiome, Ms. Lo participated in transactions totaling over US$240 million as Cardiome grew from a company with a market capitalization of US$25 million to over US$150 million at its peak. She brings with her valuable experience from the life sciences and pharmaceutical sector, as well as expertise in dealing with the complexities of operating and financing public corporations. Ms. Lo was also previously a Manager in the Transaction Services team at PwC Hong Kong and began her career articling with KPMG Vancouver. She is a Chartered Professional Accountant and holds a Bachelor of Commerce (Honours) from the Sauder School of Business at the University of British Columbia.

Mr. Victor Chang (Proposed Director)

Mr. Chang is a seasoned investor who has lately become focused on start-ups. Mr. Chang started his career with Lippo Securities Limited in 1996 and became a Director of Grand International Holdings Limited in 1999, which was engaged in general investments. During the period from 2007 to 2009, he was a Director and Responsible Officer for Astrum Capital Management Limited carrying out regulated activities under the Securities and Futures Ordinance ("SFO", Cap. 571, Laws of Hong Kong) and with Murtsa Capital Partners Limited as well. During the period from 2007 to 2012, he was also a compliance consultant for Astrum Capital Management Limited. As co-founder and Managing Director of Zebra Strategic Outsource Solution, he has over 16 years of experience in recruitment process outsourcing, executive search as well as and private investment management. In Apil 2013, he successfully brought Zebra Strategic Holdings Limited which offers holistic HR solutions to IPO on the HK GEM board (Stock Code: 8260) and was re-designated as and is currently a Non-Executive Director with the company. He is currently a Director and Responsible Officer of Dakin Financial Group, a corporation licensed to carry out type 1, 2 & 9 regulated activity under the Hong Kong Securities and Futures Ordinance.

Mr. Tong Ricky Chiu (Proposed Director)

As a key founder and visionary for Grand Power Logistics Group Inc., which was listed on the TSX Venture Exchange (GPW.V) before its privatization in 2016, and Baoshinn International Express Ltd., Mr. Chiu adds value with his immense corporate development and growth skills. He received his education in Oxford University, England, and Beijing University, and began his career in Australia. He has a diversified background in a wide range of industries with roles in finance, audit, real estate, merchandise trading and travel, as well as logistics.

Mr. James Topham (Proposed Director)

Mr. Topham is an experienced executive with expertise in finance, accounting, auditing and entrepreneurial technology companies. He was an audit partner leading KPMG's Technology Group in the Vancouver office for 20 years where he worked with many fast growing public companies and was involved in many M&A and IPO transactions in Canada, the US and Europe. Mr. Topham founded Social Venture Partners Vancouver in 2001 with a mission to strengthen the organizational capacity of innovative non-profits serving children in-need and youth at-risk. It has funded several million dollars and provided thousands of hours of executive time mentoring these local non-profits. Since retiring at KPMG 7 years ago, Mr. Topham has worked on several Boards of both public and private technology companies. He received a lifetime achievement award from the BC Technology Industry Association and was awarded the designation of Fellow Chartered Public Accountant (FCPA) from the Chartered Public Accountants of BC for his career achievements in the profession and community. He was a founder and Board member for 9 years of the BC Technology Industry Association that represents the technology industry in BC. Mr. Topham is a CPA and has a Bachelor of Commerce degree with Honours from the University of Saskatchewan graduating as the most distinguished graduate in the College of Commerce.

Mr. Allen Ma (Proposed Director)

As a 30-year technology industry veteran, Mr. Ma was the CEO of Hong Kong Science & Technology Parks before he retired in July 2016. He held senior executive positions within the information and communications technology sector. His past roles include president for Asia-Pacific at British Telecom, vice-president for Asia at the global telecom solutions sector of Motorola, executive director of Hong Kong Telecommunications - subsequently called Cable & Wireless HKT - and managing director of Hong Kong Telecom CSL. Ma holds an MBA from the University of Toronto and is a fellow member of both the Chartered Institute of Management Accountants, UK and the Association of Chartered Certified Accountants, UK. He is also a Certified Management Accountant of Canada.

Proposed Advisory Team

Novoheart is supported by a Scientific Advisory Board whose proposed composition consists of eminent scientists renowned in the fields of stem cells, cardiac biology and physiology, tissue engineering, and clinical cardiology including clinical trials research, from top academic research institutes in the U.S.A. Their technical expertise will guide the development of Novoheart as a forerunner in the application of cutting-edge technologies to develop new and better treatments for heart disease and beyond.

Further Details

Both the Company and Novoheart intend to work diligently to complete the conditions precedent to Closing and anticipate completion of the Transaction in the second quarter of 2017. The Company will update its shareholders with further details as they become available.

ON BEHALF OF WOODROSE VENTURES CORPORATION

Darren Devine, President, CEO and Director

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Completion of the Transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable pursuant to Exchange requirements, majority shareholder approval. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the Filing Statement to be prepared in connection with the Transaction, any information with respect to the Transaction may not be accurate or complete and should not be relied on. Trading in securities of the Company should be considered highly speculative.

The TSX Venture Exchange has in no way passed upon the merits of the Transaction and has neither approved nor disproved the contents of this news release.

Cautionary Note Regarding Forward-Looking Statements

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation; statements about the terms and completion of the Transaction are forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: failure to satisfy all conditions precedent to the Transaction, including shareholder approval, approval of the TSX Venture Exchange and completion of the necessary financings and the additional risks identified in the management discussion and analysis section of Woodrose Corporation's interim and most recent annual financial statement or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.

To view the photo associated with this press release, please visit the following link: http://www.marketwire.com/library/20170312-1088577_MyHeart_800.jpg

Read the original:
Woodrose Ventures Corporation Announces Proposed Acquisition ... - Marketwired (press release)

SAN DIEGO(BUSINESS WIRE)Cytori Therapeutics, Inc. (NASDAQ: CYTX) today confirmed that two Japanese regenerative medicine laws, which went into effect on November 25, 2014, remove regulatory uncertainties and provide a clear path for the Company to commercialize and market Cytori Cell Therapy and its Celution System under the Companys existing and planned regulatory approvals.

Japans new regenerative medicine laws substantially clarify regulatory ambiguities of pre-existing guidelines and this news represents a significant event for Cytori, said Dr. Marc Hedrick, President & CEO of Cytori. We have a decade of operating experience in Japan and Cytori is nicely positioned to see an impact both on existing commercial efforts and on our longer-term efforts to obtain therapeutic claims and reimbursement for our products.

Under the two new laws, Cytori believes its Celution System and autologous adipose-derived regenerative cells (ADRCs) can be provided by physicians under current Class I device regulations and used under the lowest risk category (Tier 3) for many procedures with only the approval by accredited regenerative medicine committees and local agencies of the Ministry of Health, Labour and Welfare (MHLW). This regulatory framework is expected to streamline the approval and regulatory process and increase clinical use of Cytori Cell Therapy and the Celution System over the former regulations.

Before these new laws were enacted, the regulatory pathway for clinical use of regenerative cell therapy was one-size-fits-all, irrespective of the risk posed by certain cell types and approaches, said Dr. Hedrick. Now, Cytoris point-of-care Celution System can be transparently integrated into clinical use by providers under our Class I device status and the streamlined approval process granted to cell therapies that pose the lowest risk. Our technology is unique in that respect.

Cytoris Celution System Is in Lowest of Three Risk Categories

The Act on the Safety of Regenerative Medicines and an amendment of the 2013 Pharmaceutical Affairs Act (the PMD Act), collectively termed the Regenerative Medicine Laws, replace the Human Stem Cell Guidelines. Under the new laws, the cell types used in cell therapy and regenerative medicine are classified based on risk. Cell therapies using cells derived from embryonic, induced pluripotent, cultured, genetically altered, animal and allogeneic cells are considered higher risk (Tiers 1 and 2) and will undergo an approval pathway with greater and more stringent oversight due to the presumed higher risk to patients. Cytoris Celution System, which uses the patients own cells at the point-of-care, will be considered in the lowest risk category (Tier 3) for most cases, and will be considered in Tier 2 if used as a non-homologous therapy.

Streamlined Regulatory Approval for Certain Medical Devices

In the near future, Cytori intends to pursue disease-specific or therapeutic claims and reimbursement for Cytoris Celution System and the Company would, at that point, sponsor a clinical trial to obtain Class III device-based approval and reimbursement. The new laws include changes to streamline regulation of Class II and some Class III devices, which will now require the approval of certification bodies rather than the PMDA, similar to the European notified body model. To date, certification bodies have only been used for some Class II devices.

Conditional Regulatory Approval and Reimbursement Potential

As a supplementary benefit to Cytori, the Company may also choose to take advantage of the new conditional approval opportunities granted under the new laws. Once clinical safety and an indication of efficacy are shown, sponsors may apply for their cell product to receive conditional approval for up to seven years and may be eligible for reimbursement under Japans national insurance coverage. Under the conditional approval, the sponsor can then generate post-marketing data to demonstrate further efficacy and cost effectiveness.

More here:
japanese | StemCell Therapy MD

AUTOLOGOUS Adipose Stem Cells

Stem Cell Therapy is not a new technology. As a matter of fact it has been around for more that 60 years now. The problem is most people know it as a bone marrow transplant. And well when you finish saying that people are already screaming "That's Painful". A bone marrow transplant essentially extracts stem cells from your own bone marrow and then returns them back to you. It has been used to help people suffering from conditions like Leukemia and Lymph Node Cancer.

How does it work? Stem Cells hone in on "chemokine" signals that are secreted by injury. When they arrive they alert regenerative cells to go to work and repair the damage, or grow tissue.

At birth, the human body has around 80 million active stem cells working. At age 40 we have less than 25 million active stem cells working. Therefore it takes longer for the body to heal and in some cases damage is often ignored. This is the aging or degeneration process of the body.

In 1998 a little known about Bio Tech Company discovered that there was an enormous amount of stem cells in abdominal fat, commonly referred to as Adipose fat. In fact there are about 1-2 million stem cells and regenerative cells in 1 cc of abdominal fat. Bone marrow contains less than 10% of that. The stem cells in the abdomen are in a dormant or inactive state. The challenge lay only in how to activate them.

In early 2000 the problem had been solved. A special separation process was used to isolate stem cells from abdominal fat and a perfected heliotherapy process activated the stem cells. These super-charged stem cells were now ready to go to work healing your body.

Fat Stem Cell Therapy has been used for over a decade now as therapy for a variety of medical problems as well as an alternative to painful cosmetic surgery. Fat Stem Cell Therapy can help patients suffering from medical conditions such as, Osteoarthritis, Pulmonary Disease, and Diabetes Type II, as well as some Cosmetic Procedures like Face Lifts, Breast Augmentation, and Anti-Aging.

Infinite Horizons Medical Center and its association with a leading Bio Tech company are able to deliver these high tech therapies with precision, expertise and a level of care which rivals any in the world. These painless medical procedures uses the clients' own adult stem cells to treat clients' medical problems. The procedures themselves take roughly 3.5 - 7 hours to complete.

The procedure involves extracting autologous adipose stem cells, enriching them, activating the enriched stem cells and finally returning these stem cells back into the clients' body. The procedure only requires a local anesthetic, is 100% safe, 100% effective and there is a 0% chance of rejection. For more detailed information see our procedure page.

Infinite Horizons Medical Center has put together an incredible program for clients in search of medical treatment with fat stem cell therapy for, Pulmonary Disorders, like IPF or COPD, Diabetes Type II and Osteoarthritis. It has also put together special programs with fat stem cell therapy for cosmetic procedures like Anti-Aging, Breast Augmentation and Face Lifts.

Visit link:
Fat Stem Cell Therapy

Stem Cell Therapy Plus is also called Live Cell Therapy or Regenerative Medicine.

Anecdotal evidence shows that through the usage of Stem Cell Therapy Plus, improvements can be seen in the following cases of degenerative diseases:

Learn More

Stem cells are cells with the ability to divide for indefinite periods in culture and to give rise to specialized cells. Stem cells have the remarkable potential to develop into many different cell types. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells.

When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a nerve cell, or a brain cell.

Stem Cell Supplements are developed based on the merits of stem cells and they are applied for degenerative diseases treatments and to stimulate the formation of all the different tissues of the body: muscle, cartilage, tendon, ligament, bone, blood, nerve, organs, etc.

Stem Cell Supplements bring essential anti-ageing, health & beauty benefits by providing necessary elements to the body to improve cellular regeneration, organ rejuvenation and tissue healing.

Learn More

View original post here:
Stem Cell Therapy in Switzerland Life Cell Injections ...

Nonsurgical pain management for joint arthritis, such as in the knee, shoulder or hip, has so far consisted predominantly of pain suppressing medicines. This usually entails steroid injections, topical analgesic creams and medications by mouth such as anti-inflammatory medications. What has really been necessary, though, is a treatment that truly alters the underlying problem.

Stem Cells are like a blank slate and can differentiate into all types of cells for regeneration.

Regenerative medicine provides the opportunity for a real cure with stem cells, platelet rich plasma and growth factors to heal damage. One of the foremost procedures at TeleHealth Medical Group that continues to increase in popularity is bone marrow derived stem cell injections. A persons own bone marrow contains a substantial amount of the stem cells and additional biologic materials necessary for regeneration, with the added benefit of being low risk and outpatient.

What are bone marrow derived stem cell injections?

The main reason that stem cells are used as therapy for arthritis and other conditions that experience joint pain is that they maintain regenerative properties with the potential to repair and reverse damaged joints.

Bone marrow is a spongy tissue contained inside ones bones, and makes cells that are crucial to existence including platelets, white blood cells and red blood cells. All of these cells start in the marrow as stem cells, which are basically a blank slate type of cell. With a blank slate, the cell can then turn into many different types of cells needed in the body including cartilage, tendon or muscle. There are three types of adult stem cells in the human body. The first type of stem cell turns into blood components, with a second destined to become lining of the endometrium.

The third, and most important for musculoskeletal regenerative medicine, are mesenchymal stem cells found in bone marrow. They have been used in animal models to regenerate cartilage and in human models to regenerate bone. (Centeno et al, 2008)

The largest and easiest sources of stem cells for concentrated amounts of bone marrow are in the iliac crest of the hip and the bones of the spine. For the easiest process at TeleHealth, the iliac crest is used for the procedures in an outpatient setting.

Harvesting bone marrow from the iliac crest hip bone.

How are these injections performed?

Original post:
Bone Marrow Stem Cell Injections, Mesenchymal Stem Cell ...

San Diego, California (PRWEB) October 28, 2014

The top stem cell clinic in San Diego, Telehealth, is now offering regenerative medicine procedures for the knee to help restore cartilage and avoid the need for joint replacement. The procedures are outpatient and performed by Board Certified doctors at Telehealth. Call (888) 828-4575 for more information and scheduling.

Hundreds of thousands of knee replacements are performed every year in the US, with most being extremely successful. However, it is a major surgery and there is a chance of complications such as infection or blood clot. Therefore, it is advisable to consider a stem cell procedure for the arthritic knee in an effort to delay or avoid the procedure.

Telehealth provides the procedures with several options, including platelet rich plasma therapy, bone marrow or fat derived stem cells, along with amniotic derived procedures. All of the procedures are outpatient and low risk.

In most cases, the procedures are covered in whole or partly by insurance. Telehealth will perform an insurance verification prior to one's procedure. The Board Certified doctors at the stem cell clinic in San Diego treat patients from a broad area in Southern California. There are several locations including La Jolla, Orange and Upland CA.

In addition to stem cell procedures for knee arthritis, TeleHealth also provides regenerative medicine options for tendon and ligament injuries, sports injuries along with hip, shoulder and ankle arthritis.

For those interested in avoiding knee replacement with a procedure that can potentially preserve or repair arthritic cartilage, call Telehealth at (888) 828-4575 and visit http://stemcelltherapyincalifornia.com/ for more information.

Link:
San Diego Stem Cell Clinic, Telehealth, Now Offering Knee Procedures for Cartilage Restoration

Orange County, CA (PRWEB) March 03, 2014

The top stem cell treatment clinic in Southern California, Telehealth, is now offering several knee pain treatment options for avoiding joint replacement. The regenerative medicine treatments involve either platelet rich plasma therapy, bone marrow derived stem cell injections or blood derived stem cell treatment. Call for more information and scheduling call (888) 828-4575. The treatments may be completely or partially covered by insurance.

Although knee replacement procedures have been exceptionally successful for reducing one's pain and improving functional abilities, there are some risks associated with the procedure, along with the fact they are not meant to last forever. Unlike conventional nonoperative treatments, such as steroid injections, regenerative medicine treatments maintain the ability to repair and regenerate arthritic tissue as opposed to simply masking pain.

The Board Certified doctors at Telehealth have extensive experience and regenerative medicine therapies for degenerative arthritis of the knee. Stem cell therapy for arthritis has been shown in several small published studies to provide excellent pain relief and maintain cartilage in the knee.

All of the treatments provided are low-risk and outpatient. They involve blood or bone marrow from the patient him or herself, which reduces the risk profile even more.

Telehealth Medical Group has two locations in Southern California. One is right in Santa Ana, while the other is in Upland. Appointments are readily available. Call for more information and scheduling to (888) 828-4575.

Link:
Southern California Stem Cell Clinic, Telehealth, Now Offering Several Knee Treatment Options to Avoid Joint Replacement

Orange County, California (PRWEB) December 23, 2013

The top stem cell therapy clinic in California, TeleHealth, is now offering PRP therapy for hip arthritis. The treatments are often able to delay or avoid the need for joint replacement, and are administered by Board Certified doctors at two clinic locations. Call (888) 828-4575 for more information and scheduling.

Tens of millions of Americans suffer from hip arthritis, and hundreds of thousands of hip replacements are performed every year. Nonoperative treatments prior to joint replacement often consist of steroid injections for pain relief. While the joint replacement typically has excellent pain relief outcomes, there are risks involved and sometimes the eventual need for a revision procedure.

Therefore, a procedure that offers pain relief while offering the potential for joint repair is a welcome option in hip arthritis management. TeleHealth is now offering platelet rich plasma therapy, known as PRP therapy for short, to provide pain relief and potential joint regeneration. The procedure involves a simple blood draw at the office, with the blood then being spun down in a centrifuge to obtain a solution of concentrated platelets and growth factors.

The PRP is then injected into the symptomatic hip, providing an immense amount of regenerative medicine to the arthritic joint. The material then calls in the body's stem cells as well. Published studies on PRP for joint arthritis have so far shown excellent results for pain relief.

Often times, PRP therapy at TeleHealth is covered by insurance. Verification by the clinic is able to check prior to the procedure. Patients are seen from all over Southern California for treatment of hip, knee and shoulder arthritis along with tendonitis and ligament injury. This often includes athletes, weekend warriors, executives, senior citizens and more.

To receive further information on stem cell and PRP therapy for joint arthritis or soft tissue injury, call (888) 828-4575.

See the article here:
West Coast Stem Cell Clinic, TeleHealth, Now Offering PRP Therapy for Hip Arthritis Treatment

Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function.[1] This field holds the promise of regenerating damaged tissues and organs in the body by replacing damaged tissue and/or by stimulating the bodys own repair mechanisms to heal previously irreparable tissues or organs.

Regenerative medicine also includes the possibility of growing tissues and organs in the laboratory and safely implant them when the body cannot heal itself This can potentially solves the problem of the shortage of organs available for donation, and the problem of organ transplant rejection if the organs cells are derived from the patients own tissue or cells.[2][3][4]

Widely attributed to having first been coined by William Haseltine (founder of Human Genome Sciences),[5] the term Regenerative Medicine was first found in a 1992 article on hospital administration by Leland Kaiser. Kaisers paper closes with a series of short paragraphs on future technologies that will impact hospitals. One such paragraph had Regenerative Medicine as a bold print title and went on to state, A new branch of medicine will develop that attempts to change the course of chronic disease and in many instances will regenerate tired and failing organ systems.[6][7]

Regenerative medicine refers to a group of biomedical approaches to clinical therapies that may involve the use of stem cells.[8] Examples include the injection of stem cells or progenitor cells (cell therapies); the induction of regeneration by biologically active molecules administered alone or as a secretion by infused cells (immunomodulation therapy); and transplantation of in vitro grown organs and tissues (Tissue engineering).[9][10]

A form of regenerative medicine that recently made it into clinical practice, is the use of heparan sulfate analogues on (chronic) wound healing. Heparan sulfate analogues replace degraded heparan sulfate at the wound site. They assist the damaged tissue to heal itself by repositioning growth factors and cytokines back into the damaged extracellular matrix.[11][12][13] For example, in abdominal wall reconstruction (like inguinal hernia repair), biologic meshes are being used with some success.

At the Wake Forest Institute for Regenerative Medicine, in North Carolina, Dr. Anthony Atala and his colleagues have successfully extracted muscle and bladder cells from several patients bodies, cultivated these cells in petri dishes, and then layered the cells in three-dimensional molds that resembled the shapes of the bladders. Within weeks, the cells in the molds began functioning as regular bladders which were then implanted back into the patients bodies.[14] The team is currently[when?] working on re-growing over 22 other different organs including the liver, heart, kidneys and testicles.[15]

From 1995 to 1998 Michael D. West, PhD, organized and managed the research between Geron Corporation and its academic collaborators James Thomson at the University of Wisconsin-Madison and John Gearhart of Johns Hopkins University that led to the first isolation of human embryonic stem and human embryonic germ cells.[16]

Dr. Stephen Badylak, a Research Professor in the Department of Surgery and director of Tissue Engineering at the McGowan Institute for Regenerative Medicine at the University of Pittsburgh, developed a process for scraping cells from the lining of a pigs bladder, decellularizing (removing cells to leave a clean extracellular structure) the tissue and then drying it to become a sheet or a powder. This cellular matrix powder was used to regrow the finger of Lee Spievak, who had severed half an inch of his finger after getting it caught in a propeller of a model plane.[17][18][19][dubious discuss] As of 2011, this new technology is being employed by the military to U.S. war veterans in Texas, as well as to some civilian patients. Nicknamed pixie-dust, the powdered extracellular matrix is being used success to regenerate tissue lost and damaged due to traumatic injuries.

In June 2008, at the Hospital Clnic de Barcelona, Professor Paolo Macchiarini and his team, of the University of Barcelona, performed the first tissue engineered trachea (wind pipe) transplantation. Adult stem cells were extracted from the patients bone marrow, grown into a large population, and matured into cartilage cells, or chondrocytes, using an adaptive method originally devised for treating osteoarthritis. The team then seeded the newly grown chondrocytes, as well as epithileal cells, into a decellularised (free of donor cells) tracheal segment that was donated from a 51 year old transplant donor who had died of cerebral hemorrhage. After four days of seeding, the graft was used to replace the patients left main bronchus. After one month, a biopsy elicited local bleeding, indicating that the blood vessels had already grown back successfully.[20][21]

In 2009 the SENS Foundation was launched, with its stated aim as the application of regenerative medicine defined to include the repair of living cells and extracellular material in situ to the diseases and disabilities of ageing. [22]

View post:
MD Supervised Stem Cell Therapy

Stem Cell Stories trailer - Stem Cell Therapy Europe
Stem Cell Stories trailer - Stem Cell Therapy Europe.

By: stemcelltherapy.eu

The rest is here:
Stem Cell Stories trailer - Stem Cell Therapy Europe - Video

Orange County, CA (PRWEB) October 21, 2013

The premier stem cell therapy clinic on the West Coast, Physician First Choice, is now offering IV stem cell treatment for numerous medical conditions. This includes stem cell treatment for Alzheimer's disease, Diabetes, Parkinson's, Liver Disease, Cardiac Disease, COPD and much more. The treatments are provided by US Board Certified Stem Cell Doctors and for more information call (888) 988-0515.

Stem cell therapy has become available for numerous medical conditions and can dramatically improve the patient's baseline. Increasing amounts of research are showing the benefits of IV stem cell therapy for conditions such as diabetes and COPD. Prior to stem cell therapy, these conditions could be managed with traditional medications, but the disease itself could not be altered. With stem cell therapy, that possibility exists.

The Board Certified stem cell doctors at Physician First Choice have over 20 combined years of experience working with patients for both stem cell injection treatment and IV therapy. The clinic treats patients at multiple Southern California locations along with an international location in Mexico. Patient treatment is performed by the same US Board Certified doctors before, during and after therapy to ensure continuity of care.

The program in Mexico involves four days worth of treatment at a first rate clinic, and patients stay at a beautiful hotel with transportation included. IV stem cell therapy is performed along with growth factor treatments to enhance the effect of the bone marrow stem cells.

For conditions such as multiple sclerosis, Alzheimer's or Parkinson's, watching a loved one deteriorate can be disheartening even when the best care is received. Physician First Choice has been having excellent results with IV stem cell treatment for diabetes and these conditions, and the program has been growing exponentially as a result.

The 4 Day Stem Cell Therapy IV Program is offered as a package. Transportation to and from San Diego is included along with the Hotel Stay, All Medical Treatment, Breakfast Each Day, and Transportation between the Gorgeous Hotel and the Stem Cell Treatment Facility. Patients must be approved for program inclusion with a full medical record review and evaluation by the Southern California doctors.

To inquire about program inclusion for IV stem cell therapy, call Physician First Choice at (888) 988-0515.

Read more:
Physician First Choice Now Offering IV Stem Cell Therapy for Numerous Medical Conditions with US Board Certified Stem ...

Orange, CA (PRWEB) September 30, 2013

TeleHealth, the leading stem cell therapy clinic on the West Coast, is now offering multiple treatments with stem cells for knee arthritis. The stem cell treatments are very exciting as they present the possibility of repairing and regenerating arthritis damage in the knees. The treatments are offered by Board Certified stem cell doctors at the clinic in outpatient, low risk procedures that are often covered by insurance. Call (888) 828-4575 for more information and scheduling.

Over the past few years, increasing studies are showing the benefits of regenerative medicine treatments for knee arthritis. This includes a study out of the Hospital for Special Surgery last year showing effectiveness of platelet rich plasma therapy for knee arthritis. Treatment options at TeleHealth include both platelet rich plasma therapy (PRP therapy) along with bone marrow derived stem cell injection therapy or fat derived stem cell therapy.

Often, the treatments are combined to produce maximum knee arthritis benefit and allow patients to avoid surgery, reduce pain and dramatically increase functional ability. While knee replacement surgery has been shown to have a high success rate, the components are not meant to last forever and there can be complications with the surgery.

Therefore, it makes sense to try conservative treatment prior such as with the regenerative medicine options at TeleHealth. Especially considering the stem cell treatments are often covered by insurance.

TeleHealths main stem cell clinic is located in Orange, CA, convenient to major freeways and not far from San Diego, Los Angeles, Santa Ana and Inland Empire. The highly skilled stem cell doctors at the clinic are Board Certified and have years of experience treating musculoskeletal conditions with stem cell treatments including shoulder arthritis, rotator cuff tendonitis, Achilles tendonitis, tennis elbow, muscle tears and much more.

Call (888) 828-4575 for more information and scheduling.

Read more here:
Southern California Stem Cell Therapy Clinic, TeleHealth, Now Offering Stem Cells for Knee Arthritis

Insurance Covered Stem Cell Therapy in California at TeleHealth (888) 828-4575
http://stemcelltherapyincalifornia.com Stem Cell Therapy procedures at TeleHealth are offered for a number of conditions and often covered by insurance. Thes...

By: USPainNetwork

Originally posted here:
Insurance Covered Stem Cell Therapy in California at TeleHealth (888) 828-4575 - Video

Orange County, CA (PRWEB) September 23, 2013

The leading regenerative medicine clinic on the West Coast, TeleHealth, is now offering three different types of stem cell therapy injections. The California stem cell treatments are predominantly covered by insurance, and performed by Board Certified stem cell doctors. For more information and scheduling, call (888) 828-4575.

The stem cell treatments are excellent for joint arthritis, tendonitis, ligament injuries, and spinal arthritis along with degenerative disc disease. Initial research with small studies has shown regenerative medicine treatments are working well for degenerative conditions, such as the recent study out of the Hospital for Special Surgery.

One of the treatments offered is bone marrow derived stem cell injections. These are outpatient procedures that involve harvesting the patient's own bone marrow, processing it, and injecting into the area of concern at the same setting. These bone marrow stem cell injections have very low risk and the potential for helping regenerate damaged cartilage and soft tissue from such conditions as achilles tendonitis, rotator cuff tendonitis and tennis elbow.

The second procedure offered is platelet rich plasma therapy. This procedure involves a simple blood draw from the patient, and the blood is centrifuged for approximately 15 minutes. This separates the blood into concentrated platelets and growth factors, which are then injected into the problem area. This material then calls in the body's stem cells to facilitate further repair. At times PRP is used in conjunction with bone marrow derived stem cell injections.

The third procedure utilized is fat derived stem cell injections, which has the same indications as bone marrow derived.

TeleHealth sees patients from a broad area of the west coast and offers Board Certified doctors providing treatment. To seek treatment with the premier stem cell therapy clinic, call (888) 828-4575.

Originally posted here:
Leading Stem Cell Clinic in California, TeleHealth, Now Offering 3 Different Stem Cell Therapy Treatments

Orange, CA (PRWEB) September 17, 2013

The top regenerative medicine clinic in Southern California, TeleHealth, is now offering stem cell therapy for back pain due to degenerative disc disease. The treatment has the potential to repair and regenerate damaged spinal discs and is performed as an outpatient procedure. For more information and scheduling, call (888) 828-4575.

One of the most troublesome spinal conditions to treat has been degenerative disc disease. Normally, a spinal disc contains 80% water. However, as it degenerates that percentage decreases and the discs are not great at regenerating themselves. This degeneration may unfortunately happen at a young age due to genetics or post traumatic deterioration.

TeleHealth, the leading stem cell therapy clinic in California, is now offering regenerative medicine treatments for degenerative disc disease. This includes either platelet rich plasma therapy (PRP), bone marrow derived stem cell injections, fat derived stem cell injections or a combination of therapies.

The treatments are on the cutting edge of medicine and have brought home to millions of individuals suffering from degenerative arthritis, disc disease and soft tissue injuries. TeleHealth also provides stem cell injections for osteoarthritis, rotator cuff tendonitis, achilles tendonitis, tennis elbow, ligament sprains and new indications such as hair loss and breast reconstruction after cancer.

The essential problem is that the metabolism of the degenerative disc is too slow and not able to heal itself. Stem cell treatments bring in vital reparative cells to the area along with growth factors to spur healing. The stem cell treatments for degenerative disc disease are not covered by insurance, however, most other treatments are at TeleHealth.

The treatments are all outpatient and offered by Board Certified doctors. For more information and scheduling of stem cell treatments for disc disease, call (888) 828-4575.

See the original post:
Southern California Regenerative Medicine Clinics Now Offering Stem Cell Therapy for Degenerative Disc Disease and ...